Sandoz presented its Bio100 long‑term strategy for the biosimilar business at a Capital Markets Day in London. The plan targets expanding the biosimilar portfolio from the current 13 products to more than 100 by 2040, while the company confirmed its outlook through 2028.
Background
Sandoz also indicated that it expects clear revenue growth in the coming years. The Bio100 strategy therefore includes both portfolio expansion and revenue‑growth expectations.
